Back to search

Article

Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Immunocompromised Adults in Greece: Necessity of a Fourth Dose

2022-05-19

Abstract excerpt

Real-world data suggests that protection against COVID-19 declines a few months after vaccination, particularly in the elderly and immunocompromised individuals. Our study aimed to analyze the humoral response induced by a third supplemental dose of BNT162b2 vaccine in a mixed cohort of immunocompromised individuals by determining anti-spike (anti-S) IgG antibody titers at baseline (pre-third vaccine dose) and 4 w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a0225fe1-c769-5c91-ad5f-a8199da1c6a9
DOI
10.2139/ssrn.4107959
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Immunocompromised Adults in Greece: Necessity of a Fourth DoseDOI 10.2139/ssrn.4107959
Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in GreeceSemantic proximity
Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare WorkersSemantic proximity
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Semantic proximity
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case seriesSemantic proximity
The Third Dose of the SARS-CoV-2 Vaccine: Why and for Whom?Semantic proximity
Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS StudySemantic proximity
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Semantic proximity
Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity
Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjectsSemantic proximity
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boostersSemantic proximity
Select a neighboring publication to make it the new centre.